Dual drug-loaded paclitaxel–thymoquinone nanoparticles for effective breast cancer therapy
Source abstract
Abstract
The present study highlights the beneficial synergistic blend of anticancer drug paclitaxel (PTX) and thymoquinone (TQ) in MCF-7 breast cancer cells. We aimed to augment the therapeutic index of PTX using a polymeric nanoparticle system loaded with PTX and TQ. PLGA nanoparticles encapsulating the two drugs, individually or in combination, were prepared by single emulsion solvent evaporation method. The formulated nanoparticles were homogenous with an overall negative charge and their size ranging between 200 and 300 nm. Entrapment efficiency of PTX and TQ in the dual drug-loaded nanoparticles was found to be 82.4 ± 2.18 and 65.8 ± 0.45 %, respectively. The release kinetics of PTX and TQ from the nanoparticles exhibited a biphasic pattern characterised by an initial burst, followed by a gradual and continuous release. The anticancer activity of nanoparticles encapsulating both the drugs was higher as compared to the free drugs in MCF-7 breast cancer cells. The combination index for the dual drug-loaded NPs was found to be 0.688 which is indicative of synergistic interaction. Thus, here, we propose the synthesis and use of dual drug-loaded TQ and PTX NPs which exhibits enhanced anticancer activity and can additionally help to alleviate the toxic effects of PTX by lowering its effective dose.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nigella sativa pharmacological applications · Chemotherapy-induced organ toxicity mitigation · Bioactive Compounds and Antitumor Agents
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (56)
Show source-provided references
1. Alam S, Khan ZI, Mustafa G, Kumar M, Islam F, Bhatnagar A, Ahmad FJ (2012) Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int J Nanomed 7:5705–571810.2147/IJN.S35329 ↗
2. Ali OAA, Suthama N, Mahfud LD (2014) The effect of feeding black cumin (Nigella sativa) and vitamin C on blood lipid profiles and growth performance of broilers. Int Ref J Eng Sci 3:28–33
3. Aljabre SH, Randhawa MA, Akhtar N, Alakloby OM, Alqurashi AM, Aldossary A (2005) Antidermatophyte activity of ether extract of Nigella sativa and its active principle, thymoquinone. J Ethnopharmacol 101:116–11910.1016/j.jep.2005.04.002 ↗
4. Arafa ESA, Zhu Q, Shah ZI, Wani G, Barakat BM, Racoma I, El-Mahdy MA, Wani AA (2011) Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat Res 706:28–3510.1016/j.mrfmmm.2010.10.007 ↗
5. Attoub S, Sperandio O, Raza H, Arafat K, Al-Salam S, Al Sultan MA, Al Safi M, Takahashi T, Adem A (2012) Thymoquinone as an anticancer agent: evidence from inhibition of cancer cells viability and invasion in vitro and tumor growth in vivo. Fundam Clin Pharmacol 27:1–13
6. Averineni RK, Shavi GV, Gurram AK, Deshpande PB, Arumugam K, Maliyakkal M, Meka SR, Nayanabhirama U (2012) PLGA 50:50 nanoparticles of paclitaxel: development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation. Bull Mat Sci 35:319–32610.1007/s12034-012-0313-7 ↗
7. Badary OA, Nagi MN, Al-Shabanah OA, Al-Sawaf HA, Al-Sohaibani MO, Al-Bekairi AM (1997) Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity. Can J Physiol Pharmacol 75:1356–136110.1139/y97-169 ↗
8. Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, Sarkar FH, Mohammad RM (2009) Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 69:5575–558310.1158/0008-5472.CAN-08-4235 ↗
9. Banerjee S, Padhye S, Azmi A, Wang Z, Philip PA, Kucuk O, Sarkar FH, Mohammad RM (2010) Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr Cancer 62:938–94610.1080/01635581.2010.509832 ↗
10. Banerjee S, Parasramka M, Sarkar FH, Mohammad RM (2012) Molecular insight and preclinical perspective of thymoquinone as chemopreventive agent and therapeutic adjunct in cancer. Nutr Diet Cancer 1:83–10710.1007/978-94-007-2923-0_4 ↗
11. Bojat V, Balabanyan V, Alyautdin R (2011) The entrapment of paclitaxel in PLGA nanoparticles increases its cytotoxicity against multi-resistant cell line. Br J Med Med Res 1:306–31910.9734/BJMMR/2011/382 ↗
12. Bouquet W, Ceelen W, Adriaens E, Almeida A, Quinten T, De Vos F, Pattyn P, Peeters M, Remon, JP, Vervaet C (2010) In vivo toxicity and bioavailability of Taxol® and a Paclitaxel/β-cyclodextrin formulation in a rat model during HIPEC. Ann Surg Oncol 17:2510–251710.1245/s10434-010-1028-x ↗
13. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Res 56:1649–165910.1016/j.addr.2004.02.014 ↗
14. Chavanpatil MD, Patil Y, Panyam J (2006) Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm 320:150–15610.1016/j.ijpharm.2006.03.045 ↗
15. Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70:440–44610.1158/0008-5472.CAN-09-1947 ↗
16. Danhier F, Lecouturier N, Vroman B, Jerome C (2009) Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 133:11–1710.1016/j.jconrel.2008.09.086 ↗
17. Devi TSR, Gayathri S (2010) Estimation of paclitaxel drugs by HPLC method. Der Pharma Chemica 2:109–115
18. El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA (2005) Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL60 cells. Int J Cancer 117:409–41710.1002/ijc.21205 ↗
19. El-Najjar N, Chatila M, Moukadem H, Vuorela H, Ocker M, Gandesiri M, Schneider-Stock R, Gali-Muhtasib H (2010) Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis 15:183–19510.1007/s10495-009-0421-z ↗
20. Fararh KM, Shimizu Y, Shiina T, Nikami H, Ghanem MM, Takewaki T (2005) Thymoquinone reduces hepatic glucose production in diabetic hamsters. Res Vet Sci 79:219–22310.1016/j.rvsc.2005.01.001 ↗
21. Fonseca C, Simoes S, Gaspar R (2002) Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 83:273–28610.1016/S0168-3659(02)00212-2 ↗
22. Gali-Muhtasib H, Roessner A, Schneider-Stock R (2006) Thymoquinone: a promising anti-cancer drug from natural sources. Int J Biochem Cell Biol 38:1249–125310.1016/j.biocel.2005.10.009 ↗
23. Gali-Muhtasib H et al (2008) Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells. Cancer Res 68:5609–561810.1158/0008-5472.CAN-08-0884 ↗
24. Ganguly A, Cabral F (2011) New insights into mechanisms of resistance to microtubule inhibitors. Biochim Biophys Acta-Rev Cancer 1816:164–17110.1016/j.bbcan.2011.06.001 ↗
25. Ganta S, Amiji M (2009) Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 6:928–93910.1021/mp800240j ↗
26. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS (1999) PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 57:171–18510.1016/S0168-3659(98)00116-3 ↗
27. Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H (2010) Thymoquinone and cisplatin as a therapeutic combination in lung cancer: in vitro and in vivo. J Exp Clin Cancer Res 29:2285–229610.1186/1756-9966-29-87 ↗
28. Kaur J, Tikoo K (2013) p300/CBP Dependent hyperacetylation of histones potentiates anticancer activity of gefitinib nanoparticles. Biochimica Biophysica Acta-Mol Cell Res 1833:1028–104010.1016/j.bbamcr.2013.01.029 ↗
29. Kesarwani K, Gupta R (2013) Bioavailability enhancers of herbal origin: an overview Asian Pacific. J Trop Biomed 3:253–26610.1016/S2221-1691(13)60060-X ↗
30. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Kim SW, Seo MH (2001) In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 72:191–20210.1016/S0168-3659(01)00275-9 ↗
31. Lee MK, Lim SJ, Kim CK (2007) Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28:2137–214610.1016/j.biomaterials.2007.01.014 ↗
32. Lei X, Lv X, Liu M, Yang Z, Ji M, Guo X, Dong W (2012) Thymoquinone inhibits growth and augments 5-fluorouracil-induced apoptosis in gastric cancer cells both in vitro and in vivo. Biochem Biophys Res Commun 417:864–86810.1016/j.bbrc.2011.12.063 ↗
33. Li F et al (2009) Anti-tumor activity of paclitaxel-loaded chitosan nanoparticles: an in vitro study. Mater Sci Eng 29:2392–239710.1016/j.msec.2009.07.001 ↗
34. Liggins RT, Burt HM (2004) Paclitaxel loaded poly (l-lactic acid) (PLLA) microspheres: II. The effect of processing parameters on microsphere morphology and drug release kinetics. Int J Pharm 281:103–10610.1016/j.ijpharm.2004.05.027 ↗
35. Misra R, Sahoo SK (2011) Coformulation of doxorubicin and curcumin in poly (d, l-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm 8:852–86610.1021/mp100455h ↗
36. Mu L, Feng SS (2003) PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm Res 20:1864–187210.1023/B:PHAM.0000003387.15428.42 ↗
37. Odeh F, Ismail SI, Abu-Dahab R, Mahmoud IS, Al Bawab A (2012) Thymoquinone in liposomes: a study of loading efficiency and biological activity towards breast cancer. Drug Deliv 19:371–37710.3109/10717544.2012.727500 ↗
38. Parveen S, Misra R, Sahoo SK (2012) Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 8:147–16610.1016/j.nano.2011.05.016 ↗
39. Pegram MD, Konecny GE, O’Callaghan C, Beryt M, Pietras R, Slamon DJ (2004) Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739–74910.1093/jnci/djh131 ↗
40. Ravindran J, Nair HB, Sung B, Prasad S, Tekmal RR, Aggarwal BB (2011) Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential. Biochem Pharmacol 79:1640–164710.1016/j.bcp.2010.01.023 ↗
41. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1–15
42. Ruan G, Feng S-S (2003) Preparation and characterization of poly (lactic acid)-poly (ethylene glycol)-poly (lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel. Biomaterials 24:5037–504410.1016/S0142-9612(03)00419-8 ↗
43. Sethi G, Ahn KS, Aggarwal BB (2008) Targeting nuclear factor-kB activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res 6:1059–107010.1158/1541-7786.MCR-07-2088 ↗
44. Singh A, Ahmad I, Akhter S, Jain GK, Iqbal Z, Talegaonkar S, Ahmad FJ (2012) Nanocarrier based formulation of Thymoquinone improves oral delivery: stability assessment, in vitro and in vivo studies. Coll Surf B 102:822–83210.1016/j.colsurfb.2012.08.038 ↗
45. Singla AK, Garg A, Aggarwal D (2002) Paclitaxel and its formulations. Int J Pharm 235:179–19210.1016/S0378-5173(01)00986-3 ↗
46. Surapaneni MS, Das SK, Das NG (2012) Designing paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmacol 2012:1–1510.5402/2012/623139 ↗
47. Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET, Namiki M (2007) The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate 67:955–96710.1002/pros.20581 ↗
48. Tiwari SB, Amiji MM (2006) Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J Nanosci Nanotechnol 6:3215–322110.1166/jnn.2006.440 ↗
49. Vicari L, Musumeci T, Giannone I, Adamo L, Conticello C, De Maria R, Pignatello R, Puglisi G, Gulisano M (2008) Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity. BMC Cancer 8:212–22310.1186/1471-2407-8-212 ↗
50. Wang AZ, Langer R, Farokhzad OC (2012) Nanoparticle delivery of cancer drugs. Ann Rev Med 63:185–19810.1146/annurev-med-040210-162544 ↗
51. Wang G, Yu B, Wu Y, Huang B, Yuan Y, Liu CS (2013) Controlled preparation and antitumor efficacy of vitamin E TPGS-functionalized PLGA nanoparticles for delivery of paclitaxel. Int J Pharm 446:24–3310.1016/j.ijpharm.2013.02.004 ↗
52. Woo CC, Loo SY, Gee V, Yap CW, Sethi G, Kumar AP, Benny Tan KH (2011) Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-Y pathway. Biochem Pharmacol 82:464–47510.1016/j.bcp.2011.05.030 ↗
53. Woo CC, Kumar AP, Sethi G, Tan KHB (2012) Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol 83:443–45110.1016/j.bcp.2011.09.029 ↗
54. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y, Sethi G, Aggarwal BB, Liu M (2008) Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther 7:1789–179610.1158/1535-7163.MCT-08-0124 ↗
55. Zhao L, Au JL, Wientjes MG (2010) Comparison of methods for evaluating drug-drug interaction. Front Biosci 2:241–24910.2741/e86 ↗
56. Zuo KQ, Zhang XP, Zou J, Li D, Lv ZW (2010) Establishment of a paclitaxel resistant human breast cancer cell strain (MCF-7/Taxol) and intracellular paclitaxel binding protein analysis. J Int Med Res 38:1428–143510.1177/147323001003800424 ↗